This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Veccia A , Carbonara U , Derweesh I , Mehrazin R , Porter J , Abdollah F , Mazzone E , Sundaram CP , Gonzalgo M , Mastroianni R , Ghoreifi A , Cacciamani GE , Patel D , Marcus J , Danno A , Steward J , Bhattu AS , Asghar A , Reese AC , Wu Z , Uzzo RG , Minervini A , Rha KH , Ferro M , Margulis V , Hampton LJ , Simone G , Eun DD , Djaladat H , Mottrie A , Autorino R
Single stage Xi® robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes
Minerva Urol Nephrol. 2021 Mar 29
PMID: 33781022 URL: https://www.ncbi.nlm.nih.gov/pubmed/33781022
AbstractBACKGROUND: Radical nephroureterectomy (RNU) represents the standard of care for high grade upper tract urothelial carcinoma (UTUC). Open and laparoscopic approaches are well-established treatments, but evidence regarding robotic RANU is growing. The introduction of the Xi® system facilitates the implementation of this multi-quadrant procedure. The aim of this video-article is to describe the surgical steps and the outcomes of Xi® robotic RNU. METHODS: Single stage Xi® robotic RNU without patients repositioning and robot re-docking were done between 2015 and 2019 and collected in a large worldwide multi-institutional study, the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST). Institutional review board approval and data share agreement were obtained at each center. Surgical technique is described in detail in the accompanying video. Descriptive statistics of baseline characteristics and surgical, pathological, and oncological outcomes were analyzed. RESULTSː Overall, 148 patients were included in the analysis; 14% had an ECOG >1 and 68.2% ASA ≥3. Median tumor dimension was 3.0 (IQR:2.0-4.2) cm and 34.5% showed hydronephrosis at diagnosis. Forty-eight% were cT1 tumors. Bladder cuff excision and lymph node dissection were performed in 96% and 38.1% of the procedures, respectively. Median operative time and estimated blood loss were 215.5 (IQR:160.5-290.0) minutes and 100.0 (IQR: 50.0-150.0) mL, respectively. Approximately 56% of patients took opioids during hospital stay for a total morphine equivalent dose of 22.9 (IQR:16.0-60.0) milligrams equivalent. Postoperative complications were 26 (17.7%), with 4 major (15.4%). Seven patients underwent adjuvant chemotherapy, with median number of cycles of 4.0 (IQR:3.0-6.0). CONCLUSIONS: Single stage Xi® RNU is a reproducible and safe minimally invasive procedure for treatment of UTUC. Additional potential advantages of the robot might be a wider implementation of LND with a minimally invasive approach.
Notes2724-6442 Veccia, Alessandro Carbonara, Umberto Derweesh, Ithaar Mehrazin, Reza Porter, James Abdollah, Firas Mazzone, Elio Sundaram, Chandru P Gonzalgo, Mark Mastroianni, Riccardo Ghoreifi, Alireza Cacciamani, Giovanni E Patel, Devin Marcus, Jamil Danno, Alyssa Steward, James Bhattu, Amit S Asghar, Aeen Reese, Adam C Wu, Zhenjie Uzzo, Robert G Minervini, Andrea Rha, Koon H Ferro, Matteo Margulis, Vitaly Hampton, Lance J Simone, Giuseppe Eun, Daniel D Djaladat, Hooman Mottrie, Alexandre Autorino, Riccardo Journal Article Minerva Urol Nephrol. 2021 Mar 29. doi: 10.23736/S2724-6051.21.04247-8.